Other antiviral compounds

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(14 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
−
{{ttp|p=32297571|t=2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus|pdf=|usr=}}
+
{{up|PHA antivirals by mechanism}}
 +
 
 +
 
 +
 
 
{{tp|p=32248766|t=2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 |pdf=|usr=}}
 
{{tp|p=32248766|t=2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 |pdf=|usr=}}
 +
{{tp|p=32429580|t=2020. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).|pdf=|usr=007}}
 +
{{tp|p=32423027|t=2020. COVID-19: An Update About the Discovery Clinical Trial.|pdf=|usr=007}}
 +
{{tp|p=32023685|t=2020. [Potential antiviral therapeutics for 2019 Novel Coronavirus].|pdf=|usr=007}}
 +
{{tp|p=32432977|t=2020. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.|pdf=|usr=007}}
 +
{{tp|p=32501538|t=2020. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.|pdf=|usr=007}}
 +
{{tp|p=32495848|t=2020. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.|pdf=|usr=007}}
  
  
 +
 +
'''Amantadine'''
 +
{{tp|p=32361028|t=ä. Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ? |pdf=|usr=}}
 +
{{tp|p=32361100|t=2020. Amantadine as a drug to mitigate the effects of COVID-19 |pdf=|usr=}}
 +
{{tp|p=32176361|t=2020. Potentially repurposing adamantanes for COVID-19 |pdf=|usr=}}
 +
{{tp|p=32495926|t=2020. Does amantadine have a protective effect against COVID-19?|pdf=|usr=007}}
 +
{{tp|p=32436995|t=2020. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.|pdf=|usr=007}}
 +
{{tp|p=32571606|t=2020. Amantadine Treatment for People with COVID-19.|pdf=|usr=011}}
 +
{{tp|p=32542661|t=2020. Use of amantadine in a patient with SARS-CoV-2.|pdf=|usr=011}}
 +
 +
 +
 +
'''Auranofin'''
 +
{{tp|p=32442105|t=2020. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.|pdf=|usr=007}}
 +
 +
'''Baloxavir'''
 +
{{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
 +
 +
 +
 +
'''Didanosine'''
 +
{{tp|p=32291351|t=2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data |pdf=|usr=}}
  
  
−
'''Arbidol''' retarget influenza
 
−
{{tp|p=32373347|t=2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro |pdf=|usr=}}
 
−
{{tp|p=32360231|t=ä. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?|pdf=|usr=}}
 
−
{{tp|p=32171872|t=ä. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study |pdf=|usr=}}
 
  
  
Zeile 17: Zeile 44:
  
  
−
'''Umifenovir'''
+
'''Novirin'''
−
{{tp|p=32344167|t=ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study |pdf=|usr=}}
+
{{tp|p=32283177|t=ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections |pdf=|usr=}}
  
−
'''Favipiravir'''
 
−
{{tp|p=32346491|t=ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study |pdf=|usr=}}
 
−
{{tp|p=32246834|t=2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection |pdf=|usr=}}
 
−
{{tp|p=32350860|t=2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2 |pdf=|usr=}}
 
  
−
'''Anti HCV nucleotides'''
 
−
{{tp|p=32119961|t=2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 |pdf=|usr=}}
 
  
−
'''Ritonavir'''
 
−
{{tp|p=32344308|t=2020. Suggesting Ritonavir against COVID-19/SARS-CoV-2 |pdf=|usr=}}
 
  
−
'''Didanosine'''
+
 
−
{{tp|p=32291351|t=2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data |pdf=|usr=}}
+
'''Silibinin'''
 +
{{tp|p=32517353|t=2020. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.|pdf=|usr=008}}
 +
 
 +
 
 +
 
 +
 
 +
'''Suramin'''
 +
{{tp|p=32513797|t=2020. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.|pdf=|usr=008}}
 +
 
  
 
'''Tilorone'''
 
'''Tilorone'''
 
{{tp|p=32215760|t=2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond |pdf=|usr=}}
 
{{tp|p=32215760|t=2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond |pdf=|usr=}}
 +
{{tp|p=32205350|t=2020. Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses |pdf=|usr=}}
 +
 +
 +
 +
 +
 +
 +
 +
 +
'''Anti HCV nucleotides'''
 +
{{tp|p=32119961|t=2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 |pdf=|usr=}}
 +
  
−
'''Darunavir'''
 
−
{{tp|p=32325127|t=2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients |pdf=|usr=}}
 
  
 
'''NHC'''
 
'''NHC'''
 
{{tp|p=32253226|t=ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}}
 
{{tp|p=32253226|t=ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}}
 +
{{tp|p=32253226|t=ä. (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}}
 +
 +
 +
 +
 +
'''beta ketoamides'''
 +
{{tp|p=32045235|t=ä. ?-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment |pdf=|usr=}}
 +
 +
'''some lipids'''
 +
{{tp|p=32229155|t=2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?|pdf=|usr=}}
  
−
'''Ribavirin'''
+
'''phenantroids'''
 +
{{tp|p=20727913|t=2010. (x)Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus |pdf=|usr=}}
  
−
{{tp|p=32227493|t=ä. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID?19 |pdf=|usr=}}
+
'''-'''
 +
{{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
 +
{{tp|p=31073993|t=2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives |pdf=|usr=}}
 +
{{tp|p=28945945|t=2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses |pdf=|usr=}}

Aktuelle Version vom 11. April 2021, 16:33 Uhr

PHA antivirals by mechanism



32248766 2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19
32429580 2020. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).
32423027 2020. COVID-19: An Update About the Discovery Clinical Trial.
32023685 2020. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
32432977 2020. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.
32501538 2020. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.
32495848 2020. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.


Amantadine
32361028 ä. Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ?
32361100 2020. Amantadine as a drug to mitigate the effects of COVID-19
32176361 2020. Potentially repurposing adamantanes for COVID-19
32495926 2020. Does amantadine have a protective effect against COVID-19?
32436995 2020. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.
32571606 2020. Amantadine Treatment for People with COVID-19.
32542661 2020. Use of amantadine in a patient with SARS-CoV-2.


Auranofin
32442105 2020. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.

Baloxavir
32487990 2020. Modeling mitigation of influenza epidemics by baloxavir.


Didanosine
32291351 2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data



Niclosamide
32125140 ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
32361588 2020. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19


Novirin
32283177 ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections



Silibinin
32517353 2020. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.



Suramin
32513797 2020. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.


Tilorone
32215760 2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond
32205350 2020. Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses





Anti HCV nucleotides
32119961 2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19


NHC
32253226 ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
32253226 ä. (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice



beta ketoamides
32045235 ä. ?-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment

some lipids
32229155 2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?

phenantroids
20727913 2010. (x)Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus

-
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro
31073993 2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives
28945945 2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses

Von „http://coviki.org/cov/index.php?title=Other_antiviral_compounds&oldid=677597“
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis